Media OutReach
Transforming Knee Surgery: Columbia Asia Combines Expertise and Robotics for Better Outcomes
“Our knees are subjected to wear and tear over time due to aging, injuries, and repetitive stress,” said Dr Hazli Sufian, Consultant Orthopedic Surgeon with Special Interest in Arthroplasty at Columbia Asia Hospital Tebrau. “While HA injections can help relieve pain and improve mobility in early-stage osteoarthritis, advanced cases often require knee replacement surgery for long-term relief and function.”
Dr Hazli and his surgical team have replaced conventional techniques with the CORI® robotic-assisted system by Smith+Nephew, an advanced technology designed to enhance precision and personalise knee replacement procedures.
“The CORI® system allows surgeons to capture patient-specific anatomical data in real time, enabling more precise bone preparation and soft tissue balancing,” Dr Hazli explained. “This contributes to improved joint stability, better alignment, and more natural knee movement after surgery.”
Beyond surgical precision, robotic-assisted technology improves the overall patient experience. The personalised approach can lead to reduced tissue disruption, less post-operative pain, and lower risk of complications. Many patients also benefit from enhanced mobility, greater confidence in joint function, and a potentially faster return to daily activities and rehabilitation.
By tailoring each procedure to the patient’s unique anatomy, the CORI® system supports predictable outcomes and consistent surgical results, which are key to long-term patient satisfaction.
Dr James Chong, CEO of Columbia Asia Hospital Tebrau, said the introduction of robotic-assisted knee replacement reflects the hospital’s commitment to advancing patient-centred care through innovation.
“Our investment in robotic-assisted surgery enhances not only surgical precision but also the overall patient journey—from pre-operative planning and intra-operative accuracy to post-operative recovery and rehabilitation,” he said. “This technology allows us to deliver high-quality outcomes while improving comfort, confidence, and experience for our patients.”
Hashtag: #ColumbiaAsiaHospitalTebrau #RightHereForYou #MalaysiaPRAwards2025 #PRCA #HealthcareExcellence #TeamTebrau #CommunityCare #HospitalCommunications #AwardWinningTeam #TotalKneeReplacement #RoboticTotalKneeReplacement
https://www.columbiaasia.com/malaysia/ms/hospitals/tebrau/
https://www.linkedin.com/company/columbia-asia-malaysia/about/
https://x.com/columbiaasia
https://www.facebook.com/columbiaasia
https://www.instagram.com/columbiaasia/https://www.facebook.com/@ColumbiaAsiaHospitalTebrau
The issuer is solely responsible for the content of this announcement.
About Columbia Asia Hospital Tebrau
Columbia Asia Hospital Tebrau is dedicated to serving the healthcare needs of the Johor community with compassion, professionalism, and clinical excellence. Equipped with advanced medical technology—including a Cardiac Catheterization Laboratory, Mammography services, a 128-slice CT Scan, and a 1.5 Tesla MRI—the hospital delivers comprehensive diagnostic and treatment capabilities to support timely and accurate clinical decision-making.
The hospital offers a broad range of medical specialties, including Cardiology, Nephrology, Internal Medicine, Maternal Fetal Medicine, Ear, Nose & Throat (ENT), General Surgery, Obstetrics & Gynecology (O&G), Respiratory Medicine, Orthopaedics, and Dermatology. A fully operational 24/7 Emergency Room, supported by on-call Emergency Physicians, ensures that patients receive immediate and appropriate care at any time of the day.
At the core of Columbia Asia Hospital Tebrau’s philosophy is a strong commitment to personalized, patient-centred care—ensuring that every individual feels heard, supported, and well cared for throughout their healthcare journey.
Looking ahead over the next five years, Columbia Asia Hospital Tebrau will align its strategic direction with Rancangan Malaysia Ke-13 (RMK-13), with a focused emphasis on addressing Non-Communicable Diseases (NCDs). In particular, the hospital will strengthen its efforts in obesity management through integrated, multidisciplinary care models encompassing prevention, early intervention, medical management, surgical intervention and long-term follow-up. This reflects a proactive approach to tackling one of the most pressing public health challenges affecting the Johor community.
In parallel, the hospital has advanced its surgical capabilities through the adoption of robotic-assisted surgery. This investment is aimed at enhancing surgical precision, improving clinical outcomes, reducing recovery times, and elevating overall patient experience, in line with global best practices.
To meet the growing healthcare demands of Johor, Columbia Asia Hospital Tebrau is also planning for future expansion, including the addition of more inpatient beds. This expansion will enable the hospital to better serve the increasing needs of the community while maintaining high standards of safety, quality, and accessibility in care delivery.
Through strategic alignment, technological advancement, and capacity expansion, Columbia Asia Hospital Tebrau remains committed to supporting the long-term health and well-being of the Johorean population.
About Columbia Asia
For 30 years, Columbia Asia Group of hospitals has been at the forefront of quality healthcare in the private healthcare industry. Established in 1996, it has evolved from its first hospital in Shah Alam to its latest in Penang, to date. As an international healthcare provider, its services span across 19 hospitals in the region; 13 in Malaysia, five in Indonesia, and one in Vietnam. Through the years, the company strategy has always been about making private healthcare accessible to all, hence its hospitals are strategically located in densely populated areas. Under the umbrella of private healthcare company, Asia OneHealthcare, the Columbia Asia group has expanded its reach to bring not just world-class, but also effective healthcare, closer to home.
Through the years, Columbia Asia’s emphasis has consistently been about early detection of diseases. This is carried out by way of advanced technology for precise diagnostics, resulting in minimally invasive procedures. To fulfil the typical healthcare needs of communities, Columbia Asia offers core disciplines such as obstetrics & gynecology, pediatrics, and general surgery. Today, it also provides tertiary healthcare addressing more complex fields of medicine such as neurosurgery, cardiac disease treatments, and integrated cancer care.
As it approaches a new decade, Columbia Asia continues to expand; adopting cutting-edge technology to meet the ever-increasing needs of today’s discerning customers. Upholding strict clinical governance, medical ethics and acknowledged by the Malaysian Society for Quality in Health, Columbia Asia continues to deliver excellent patient outcomes in a safe and trusted environment.
Columbia Asia. Right Here For You.
Through DaaS, enterprise customers can access drone equipment, trained personnel, mission execution, data collection and project deliverables without purchasing and maintaining a complete in-house drone system. The model extends ZenaTech’s business beyond equipment sales and enables the company to generate recurring service revenue from customers’ operational requirements.
ZenaTech reported revenue of CAD 8.4 million for the first quarter of 2026, an increase of 640% from CAD 1.13 million in the same period of 2025. DaaS contributed approximately CAD 7.8 million, accounting for around 93% of quarterly revenue.
In 2025, the company generated annual revenue of CAD 12.9 million, up 558% from approximately CAD 2 million in 2024. DaaS contributed approximately CAD 10.1 million during its first full year of operations, representing around 78% of total annual revenue.
Acquisitions Support Service Network Expansion
ZenaTech has expanded its DaaS operations through a combination of internal technology development and acquisitions. The acquired businesses bring existing customers, professional teams and local operating capabilities, while ZenaTech gradually introduces drones, automated data collection and AI-supported analytics into selected workflows.
In 2025, the company completed 20 acquisitions, including 19 businesses providing engineering data, facility inspection and related professional services, as well as one enterprise software company.
By June 2026, ZenaTech had completed its 24th DaaS-related acquisition and expanded its services into property cleaning, facility inspection and maintenance.
Through its ZenaDrone subsidiary, ZenaTech has also developed drone products for indoor and outdoor operations. The IQ Quad supports site data collection, engineering imagery and 3D modelling, while the IQ Nano uses barcode and RFID scanning to support inventory records, shelf inspections and indoor data collection.
The company’s reported revenue growth, acquisition activity and DaaS contribution provide investors following the AI and drone sectors with measurable indicators of how its technologies are being integrated into commercial operations and converted into service revenue.
Hashtag: #ZenaTech
The issuer is solely responsible for the content of this announcement.
About ZenaTech
ZenaTech (Nasdaq: ZENA) is a technology company specialising in AI-powered drones, Drone-as-a-Service (DaaS), enterprise SaaS solutions and related technologies. Through its ZenaDrone subsidiary, the company develops drone products and software for commercial applications including engineering data collection, agriculture, warehouse management, facility inspection and property maintenance. ZenaTech combines its technology capabilities with a growing professional service network to support the adoption of drone-based solutions across a range of operational environments.
Media OutReach
A Defining Milestone for Gene Solutions: SPOT-MAS Multi-Cancer Screening Test Receives U.S. FDA Breakthrough Device Designation
The proposed indications for use describe SPOT-MAS 10 as a qualitative in vitro diagnostic test performed on plasma derived from a single direct-draw venous whole blood specimen. The test analyzes circulating cell-free DNA methylation and fragmentomic signatures using a machine-learning-based algorithm to detect a cancer-associated signal. It is intended for use as an adjunctive screening test in asymptomatic adults aged 40 years and older to assist in detecting cancers within the scope of the assay. These include five common cancers — breast, lung, liver, colorectal and gastric cancers — and five aggressive, less common cancers that currently lack standard screening methods — ovarian, pancreatic, esophageal, endometrial and head & neck cancers.
SPOT-MAS has been developed through years of rigorous scientific research and clinical development. In March 2025, SPOT-MAS became the first multi-cancer screening blood test in Asia to complete a large prospective cohort validation, with the K-DETEK study evaluating more than 9,000 asymptomatic participants and demonstrating strong performance, including high specificity and the ability to identify cancer-associated signals across multiple cancer types.
Since then, SPOT-MAS has been used in more than 100,000 individuals in real-world practice, with consistent performance observed beyond controlled study settings. Real-world data were presented at ESMO Asia 2025 and were featured at ASCO Breakthrough 2026 in Singapore.
The platform is built on a multi-omic approach— integrating genetics, epigenetics, and fragmentomics — together with AI-driven analysis, large-scale prospective validation, growing real-world evidence and focus on cancer types with high clinical relevance in the regions where the test is deployed.
For the United States, Breakthrough Device Designation provides Gene Solutions with a prioritized channel of engagement with the FDA as the company advances its U.S. development and validation plans.
Looking ahead, Gene Solutions will continue to collaborate with academic, clinical, laboratory, commercial and strategic partners to support responsible adoption of SPOT-MAS in accordance with local regulations, clinical guidelines and best practices.
Important Regulatory Notice: SPOT-MAS 10 has received U.S. FDA Breakthrough Device Designation. Breakthrough Device Designation is not FDA approval, clearance or marketing authorization. The device remains subject to applicable FDA regulatory review requirements, and the designation does not guarantee future FDA approval, clearance or authorization.
For more information, visit https://spotmas.com.hk
Contact:
hk***@***********ns.com
Source: Gene Solutions Hong Kong Limited.
SPOTMAS_062026_04
Hashtag: #SPOTMAS
https://spotmas.com.hk/The issuer is solely responsible for the content of this announcement.
Media OutReach
St Francis Methodist School International Shares 2023–2024 WACE Outcomes and Student Journeys
Overview of the WACE Curriculum at SFMS
SFMS International is among a small number of institutions in Singapore offering the WACE curriculum and has delivered this programme for over 23 years. The WACE is a recognised senior secondary qualification awarded by the School Curriculum and Standards Authority (SCSA) on behalf of the Ministry of Education, Western Australia. It prepares students for university admission both locally and internationally.
SFMS is also currently the only school in Singapore offering a Senior High Preparatory Pathway (WACE) for students in Years 9–10. This introduces students to the structure and expectations of the curriculum earlier, building familiarity with subject content and assessment formats before progressing to the senior years. Additionally, subject selection in Years 11A and 12A is structured to meet university entry requirements and reflect students’ academic interests.
Academic Outcomes and University Placements
In 2023, 8 out of 12 WACE graduates from SFMS International achieved ATAR scores above 90, meeting the eligibility criteria for universities such as the National University of Singapore (NUS) and Nanyang Technological University (NTU). The cohort’s top scorer, Wang Dawei, recorded an ATAR of 96.15 and enrolled at NTU to study Business and International Trading. In addition to local placements, graduates were admitted to international universities such as the University of Melbourne and Fudan University in China.
In 2024, 2 out of 8 graduates also attained ATAR scores above 90. The highest scorer, Youn Chae-Won, achieved an ATAR of 95.3. Her university placement is currently pending.
Student Journeys and Holistic Development
Students in the WACE programme at SFMS International engage in both academic and co-curricular activities as part of their overall learning experience. Recent graduates have taken part in service learning, subject specialisation, and personal reflection throughout their time in the pre-university programme.
Youn Chae-Won, the 2024 valedictorian, joined SFMS International from Korea in 2021. Over time, she adjusted to a new academic environment and explored subjects such as accounting, which influenced her interest in finance-related pathways. She also took part in various aspects of school life, including a service learning trip to Bintan in 2023, where students supported local sanitation efforts. Her involvement in both academic and co-curricular settings marked a broad engagement with school life during her time at SFMS.
Andrew Zhuang, who enrolled in SFMS International in 2019, pursued subjects such as Business Management, Accounting, and English as an Additional Language (EALD). Beyond academics, he was involved in community fundraising and joined the same Bintan service trip. He also attended weekly chapel sessions and received support from peers and teachers during a period of health-related absence.
These outcomes reflect the ongoing role of the WACE programme at SFMS International in supporting students through both academic pathways and broader educational experiences. Under the leadership of Principal Mr Lee Hak Boon, the school continues to emphasise academic planning, subject selection, and student wellbeing as part of its overall approach to pre-university education.
Hashtag: #StFrancisMethodistSchoolInternational
https://www.sfms.edu.sg/
https://www.facebook.com/sfms.singapore
https://www.instagram.com/sfms_sg/
https://www.youtube.com/channel/UC_bb9hcNhAk7WgYBE_FI61A/featured
The issuer is solely responsible for the content of this announcement.
About St Francis Methodist School International
Established in 1960, St Francis Methodist School International (SFMS) is an educational institution in Singapore that offers primary, secondary, and pre-university programmes. The school provides several academic pathways, including the International Baccalaureate (IB), Cambridge IGCSE, and the Western Australian Certificate of Education (WACE), preparing students for further studies in local and overseas institutions.
